Association of HPV35 with cervical carcinogenesis among women of African ancestry: Evidence of viral-host interaction with implications for disease intervention.
Adult
Africa South of the Sahara
/ ethnology
Black or African American
/ statistics & numerical data
Female
Genetic Variation
Humans
Middle Aged
Papillomaviridae
/ classification
Papillomavirus Infections
/ epidemiology
Phylogeny
Precancerous Conditions
/ epidemiology
Prevalence
United States
/ ethnology
Uterine Cervical Neoplasms
/ epidemiology
Uterine Cervical Dysplasia
/ epidemiology
African ancestry women
HPV35
cervical cancer
epidemiology
genetics
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 11 2020
15 11 2020
Historique:
received:
10
07
2019
revised:
20
03
2020
accepted:
02
04
2020
pubmed:
5
5
2020
medline:
17
4
2021
entrez:
5
5
2020
Statut:
ppublish
Résumé
HPV35 has been found in only ∼2% of invasive cervical cancers (ICC) worldwide but up to 10% in Sub-Saharan Africa, warranting further investigation and consideration of impact on preventive strategies. We studied HPV35 and ethnicity, in relation to the known steps in cervical carcinogenesis, using multiple large epidemiologic studies in the U.S. and internationally. Combining five U.S. studies, we measured HPV35 positivity and, in Northern California, observed HPV35 type-specific population prevalence and estimated 5-year risk of developing precancer when HPV35-positive. HPV35 genetic variation was examined for differences in carcinogenicity in 1053 HPV35+ cervical specimens from a U.S. cohort and an international collection. African-American women had more HPV35 (12.1% vs 5.1%, P < .001) and more HPV35-associated precancers (7.4% vs 2.1%, P < .001) compared to other ethnicities. Precancer risks after HPV35 infection did not vary by ethnicity (global P = .52). The HPV35 A2 sublineage showed an increased association with precancer/cancer in African-Americans (OR = 5.6 vs A1, 95% CI = 1.3-24.8) and A2 was more prevalent among ICC in Africa than other world regions (41.9% vs 10.4%, P < .01). Our analyses support a strong link between HPV35 and cervical carcinogenesis in women of African ancestry. Current HPV vaccines cover the majority of cervical precancer/cancer across all ethnic groups; additional analyses are required to determine whether the addition of HPV35 to the already highly effective nine-valent HPV vaccine would provide better protection for women in Africa or of African ancestry.
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2677-2686Subventions
Organisme : NIH HHS
ID : P30CA013330
Pays : United States
Organisme : NCI NIH HHS
ID : CA78527
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Informations de copyright
© 2020 UICC.
Références
de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-1056.
Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-part B: biological agents. Lancet Oncol. 2009;10:321-322.
Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675-2686.
Global Burden of Disease Cancer Consortium, Fitzmaurice C, Allen C, et al. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524-548.
Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131:2349-2359.
Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107:djv086.
Hariri S, Steinau M, Rinas A, et al. HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001-2006. PLoS One. 2012;7:e34044.
Liu G, Unger ER, Hariri S, Steinau M, Markowitz LE. Prevalence of 9-Valent human papillomavirus types by race/ethnicity in the Prevaccine era, United States, 2003-2006. Sex Transm Dis. 2016;43:633-636.
Vidal AC, Smith JS, Valea F, et al. HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA. Cancer Causes Control. 2014;25:1055-1062.
Clifford GM, de Vuyst H, Tenet V, Plummer M, Tully S, Franceschi S. Effect of HIV infection on human papillomavirus types causing invasive cervical cancer in Africa. J Acquir Immune Defic Syndr. 2016;73:332-339.
Ali-Risasi C, Verdonck K, Padalko E, vanden Broeck D, Praet M. Prevalence and risk factors for cancer of the uterine cervix among women living in Kinshasa, The Democratic Republic of the Congo: a cross-sectional study. Infect Agent Cancer. 2015;10:20.
Castellsague X, Klaustermeier J, Carrilho C, et al. Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention. Int J Cancer. 2008;122:1901-1904.
Okolo C, Franceschi S, Adewole I, et al. Human papillomavirus infection in women with and without cervical cancer in Ibadan, Nigeria. Infect Agent Cancer. 2010;5:24.
Denny L, Adewole I, Anorlu R, et al. Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer. 2014;134:1389-1398.
Hopenhayn C, Christian A, Christian WJ, et al. Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction. J Low Genit Tract Dis. 2014;18:182-189.
Food and Drug Administration. Highlights of Prescribing Information. Gardasil 9 (Human Papillomavirus 9-Valent Vaccine, Recombinant). Suspension for Intramuscular Injection Initial U.S. Approval. Silver Spring, MD: FDA; 2014.
Mirabello L, Yeager M, Cullen M, et al. HPV16 sublineage associations with histology-specific cancer risk using HPV whole-genome sequences in 3200 women. J Natl Cancer Inst. 2016;108:djw100.
Xi LF, Kiviat NB, Hildesheim A, et al. Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst. 2006;98:1045-1052.
Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 2013;445:232-243.
Schiffman M, Rodriguez AC, Chen Z, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res. 2010;70:3159-3169.
LaMere BJ, Howell R, Fetterman B, Shieh J, Castle PE. Impact of 6-month frozen storage of cervical specimens in alkaline buffer conditions on human papillomavirus genotyping. J Virol Methods. 2008;151:298-300.
Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383-1392.
A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:1393-1400.
Wang SS, Zuna RE, Wentzensen N, et al. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev. 2009;18:113-120.
Wentzensen N, Walker JL, Gold MA, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol. 2015;33:83-89.
Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378-384.
Hyun N, Cheung LC, Pan Q, Schiffman M, Katki HA. Flexible risk prediction models for left or interval-censored data from electronic health records. Ann Appl Stat. 2017;11:1063-1084.
Wentzensen N, Schiffman M, Dunn T, et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer. 2009;125:2151-2158.
Gage JC, Ajenifuja KO, Wentzensen NA, et al. The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies. Int J Cancer. 2011;130(9):2111-2117.
Hariri S, Unger ER, Schafer S, et al. HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States. Cancer Epidemiol Biomarkers Prev. 2015;24:393-399.
Pimenoff VN, Tous S, Benavente Y, et al. Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: results from a worldwide cross-sectional study. Int J Cancer. 2019;144:2478-2488.
Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
Xi LF, Koutsky LA, Hildesheim A, et al. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev. 2007;16:4-10.
Chen Z, DeSalle R, Schiffman M, et al. Niche adaptation and viral transmission of human papillomaviruses from archaic hominins to modern humans. PLoS Pathog. 2018;14:e1007352.
Pimenoff VN, de Oliveira CM, Bravo IG. Transmission between archaic and modern human ancestors during the evolution of the oncogenic human papillomavirus 16. Mol Biol Evol. 2017;34:4-19.
Reddy D, Njala J, Stocker P, et al. High-risk human papillomavirus in HIV-infected women undergoing cervical cancer screening in Lilongwe, Malawi: a pilot study. Int J STD AIDS. 2015;26:379-387.
Warren CJ, Westrich JA, Doorslaer KV, Pyeon D. Roles of APOBEC3A and APOBEC3B in human papillomavirus infection and disease progression. Viruses. 2017;9:233.